Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: case series. | J Yeungnam Med Sci;39(1): 62-66, 2022 Jan. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (tislelizumab) therapy in patients with advanced gastric cancer: case series.

Baek, Jin Ho.

Affiliation

Baek JH; Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.

J Yeungnam Med Sci ; 39(1): 62-66, 2022 Jan.

Article in En | MEDLINE | ID: mdl-33866751

Key words

Adverse events; Immune checkpoint inhibitors; Tislelizumab; stomach neoplasms

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Screening_studies Language: En Journal: J Yeungnam Med Sci Year: 2022 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Screening_studies Language: En Journal: J Yeungnam Med Sci Year: 2022 Document type: Article Country of publication: